Hero

Celyad to Present Data at 24th Congress of the European Hematology Association

1

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

2

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces May 2019 Investor Conference Schedule

Celyad Announces May 2019 Investor Conference Schedule

Discover all news

Carousel

Social Feed

@LehmannFrdric1, Celyad's VP Clinical Development & Medical Affairs is a keynote speaker at the Cell Therapy innova… https://t.co/P9dqwZWPGr

5 days ago

@LehmannFrdric1, Celyad's VP Clinical Development & Medical Affairs is a keynote speaker at the Cell Therapy innova… https://t.co/P9dqwZWPGr

Did you know that Belgium is the 2nd country in the EU with the largest number of clinical trials ? $CYAD… https://t.co/RHEs8952kb

6 days ago

Did you know that Belgium is the 2nd country in the EU with the largest number of clinical trials ? $CYAD… https://t.co/RHEs8952kb

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

1 week ago

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

1 week ago

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

@LehmannFrdric1, Celyad's VP Clinical Development & Medical Affairs is a keynote speaker at the Cell Therapy innova… https://t.co/P9dqwZWPGr

5 days ago

@LehmannFrdric1, Celyad's VP Clinical Development & Medical Affairs is a keynote speaker at the Cell Therapy innova… https://t.co/P9dqwZWPGr

Did you know that Belgium is the 2nd country in the EU with the largest number of clinical trials ? $CYAD… https://t.co/RHEs8952kb

6 days ago

Did you know that Belgium is the 2nd country in the EU with the largest number of clinical trials ? $CYAD… https://t.co/RHEs8952kb

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

1 week ago

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

1 week ago

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454